



ADVISORY

No. 269

November 15, 2024

Brand vs Generic (DAW6) Changes to Maryland Medicaid's Preferred Drug List (PDL)

Effective December 6, 2024:

The Office of Pharmacy Services (OPS) wants to alert you that effective December 6, 2024:

- **Brand Ritalin LA, Brand Risperdal Consta and Brand Farxiga will be preferred** over its respective generic equivalent. Claims for brand Ritalin LA, Risperdal Consta and Farxiga must be submitted with DAW 6 code and will be priced appropriately. A Maryland Department of Health (MDH) MedWatch form will not be required. Claims with any other DAW code will reject.

If any problems are encountered during the online claim adjudication, contact Conduent 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance).

Please refer to our website for the Preferred Drug List (PDL) and Brand Preferred over Generics List:
<https://health.maryland.gov/mmcp/pap/pages/Preferred-Drug-List.aspx>

All Advisories are available online on MDH's web link at:
<https://health.maryland.gov/mmcp/pap/Pages/Provider-Advisories.aspx>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Office of Pharmacy Services (OPS)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the OPS representative at 410-767-1455.